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haamatoc~ w~e cell count ONCC)) in 64 paUents (43 male; mean age 63.2 
years, s.d. 8.9) admitted with acute stroke (ictus onset < 12 hours). Levels 
of these madrms and blood pressures (BPs, mmHg) were compared to 21 
healthy controls (age 6t .5 years, s.d. 11.7). Our results are shown in the table. 
There were no significant differences in these markers and BPs between 
patients who were alive or dead (n = 13) aner 6 months followup. Plasma 
viso0sity was s in i f~  cormtatad to fibrinogen (r = 0,5,p < 0.001) and vWf 
(r = 0.3, p = 0.04). Stepwise mul~ple regression analysis demonstrated that 
faxinogen a.d diasfoli~ UPs were predictors for plasma viscosity (p = 0,018). 
Onty the WGC level was a pre~ctor for flbrinogen levels (p = 0.03). There 
were no s'~nificaat pmo'ictsrs for vWt and P-selectin levels. Despite eady 
pmsentatfon (< 12 Itours) patients with acute stroke have haemorhnolngical 
abhorrences (l~odnogen, WCG and plasma viscosity), ptatofot dysfunoUan 
(with raised P-seio~Jn) and endothelial dysfunction (with high vWf), Tilase 
abnormalities may act synergistically inthe p~thogenasis ofacute stroke and 
its complications, 
PHARMACOLOGY-  BASIC 
~ T w o  Intracoronary Ooses of Basic Fibroblast 
Growth Factor Enhance Collateral Blood ROw in 
oogs 
Shennini Rajanayagam, M~e Sbou, Venogepal Thimmudi, Everett Hedge, 
Daisy F:. Lazarens, Amhed A. Quyyend, Stephen E, Epstein, Ellis F. Unger. 
~wology Branch, NHLBI, Bethasda, MD 
Bask= flbreblast growth factor (bFGF), an angiogenic growth factor, is cur- 
rently the subject of a Phase I clinical thai in pts wiih ischemic heart disease 
(IHD). In a Canine model of single vessel coronary occlusion, we previously 
demonstrated that bFGF enhances collateral blood flow (CBF) when given 
as a daily I.C, bolus for 4 weeks, or as a deJly left atrial bolus for 7 days; 
however, these schedules and mutes of administration would not be practl~ 
cal in pts with IHD. To establish a feasible mute of drug delivery and to limit 
potential systemic toxicity, we determined whether injection of bFGF into the 
left main coronary artoly would enhance CBR A second aim was to astab. 
fish the minimum effective course of bFGF b'eatment. Dogs were subjected 
to amemkHnducod occlusion of the left circumflex nsmnary adew. Subse- 
qUeotly, the dogs undelwent cardiac cathatedza~on a d were randomized to 
receive bFGF 0.1 mg/kg as a bolus into the left main coronmy artery twice 
(14 and 16 days after amereid placement, n = 10) or once (day 16, n = 8), 
A control group received the vehicle (n = 10), CBF was assessed dudng 
maximal coronaq/vasodilatation with radiolsheled microsphems on day 33, 
Maximal CBF in dogs ~ received bFGF twice was 2.39 :E 0.09 ml/min/g, 
exceeding that of control dogs by 39=/0 (1.72 :E 0.13 ml/miNg, mean :E SE; 
P < 0.0005), Dogs that received a single dose Of bFGF had an intermediate 
flow (2.10 :E 0.21 ), statistically indistinguishable from the other gmupe. Thus, 
two doses of bFGF administered into the left main coronary anery were suf~ 
fioient to improve CBF, an inteprention that is feasible in pts with IHD, These 
data provide the basis for a tdal of inIJracomnaty bFGF in pts with IHD. 
Effects of Mao.1 Inhibitor on Hemostasis During 
Myocardial Stunning in Swine 
Victor L. Sembrusny, Andrew R, Shustov, Paul A. Gurhel, William 
R. Herzog. University of Maryland, Baltimore, MD 
The impodant role of hemestatic disorders has been Increasingly recog- 
nized in patients with myocardial ischemia. NPG 15669 is a member of the 
leumadins, and inhibits leukocyte adhesion to the endothniium by blockage 
of Mac-1 upregulalion. The effects of NPC 15669 supplementation on the 
hemostatfo profile dedng myocazdial stunning (MS) are poorly understood. 
Thus, the puq~ese of this project was tO link potential changes in hamestalJc 
profile with NPC 15669 therapy dudng mild MS in in v/vo anin~ ntodel. 
Twelve opeo<dlasted Yorkshire swine underwent LAD occlusion for 8 
minutes followed by 90 minutes of reperfusion. Blood samples were obtained 
at baseline, at 4 and at 8 minutes of OcClusion, and at 60 ~',d 90 minutes 
of reped~Jsion, NPC 15669 (10 mg/kg loading dose followed by constant 
infusion at 6 rag/k9 -1/11 -t) was administered in 6 animals; another 6 swine 
received saline end served as conlmls. Coneenlmtions of antithrombth-III 
(AT-Ill), Protein C, total Protein S, ftb~ne~n, endothniin-t lET-l), as well 
as the stable metabulitss of thmmboxane (TxB~) and prostacydin (6-keto- 
PGFI=), were measured in the systemic cin~l~ion, Treatment with NPC 
15669 was assedalsd with diminished ETol (37,4%), 6-kato-PGFla (47.1%) 
levels and inornased fibmno~in (77.6%) concentrations during MS, There 
were no changes in the plasma cenceatrations of TxB.z, total protein S, 
protein C and AT-Ill in NPC 15669 group when compared with controls. 
Mild MS ts as~sociatsd with sobstantial dynamio changes in the hanlestatfo 
profile. NPC 15669 administration i  a swine model of MS alfe¢ls spenif'¢ 
hemostatls parameters. This data provl~s lrong support for the involvement 
of cellular ~ ls rns  and endothelial dyshmc~on in the petbogenesls of 
MS. The ability of the drug to modulate hemostasis may have implications 
for the use of lsumedins in cardiovascular drseese. 
PHARMACOLOGY-  CL IN ICAL  
Effect of Calcium Channel Blockers on the 
Incidence of Myocardial Infarction in Patients 
With Left Ventdcular Dysfunction 
John B. Kostis, Alan C, Wilson, Nora M. Cosgn)ve, Clifton R, lacy, from the 
UMDNJ-Robert Wood JohnSon Medical SchOOl Clinical Center Based on 
the SOLVD Database. UMDNURobert Wood Johnson Medical School, New 
Brunswick, NJ 
Recent studies have suggested an increased risk of myocardial infarction (MI) 
in patients on calcium channel blockers (CCB). We evaluated the effect of 
CCB on fatal and non-fatal MI in 6797 patientS with left ventricular dysfunction 
(LVD, EF < 35%) in the Studies Of Left Ventdcular DysfuncUan (SOLVD). 
During 40 months average follow-up, fatal or non.fatal MI occurred in 11.5% 
of the 845 patientS on CCB dudng follow-up versus 7.5% of the 255t patients 
not on CCB (,0 ~= 0.001, O.R. 1.6195% Cl 1.24-2,07) in the enalupdl group; 
and in 14.4% of the 874 patients on CCB versus 9,3% of the 2527 patients not 
on CCB (p = 0.001, O,R. 1.64; CI 1.30-2.06) in the placebo group, 
By multivariate Cox regression analysis, adjus~ng for 29 variables descch- 
log demographics, Gomorblddy, e~oiooy and sovedty of LVD, head failure, 
and cancomitont drug use, CCB use dudng follOw-up was an independent 
predictor of increased dsk (R.R. 1.37; CI 1.14-1.63), 
The increased dsk associated with CCB was also observed when the 
combined endpoint of MI, cardiac death, or hospitalization for angina was 
considered. The incrcased MI risk was obsen/ed whether CCB were used 
both at baseline and follow-up or only at follOw-up. In addition, the risk was 
higher when the mean follow-up heart rate Of pa~ents on CCB was higher 
than the median follow-up rate of patients on CCB (74 beats/minoto). 
In contrast~ using the same database and analysis, beta 104od,,m use was 
assodated with a lower rate of fatal or non-fatal MI (multivariate Cox R.R. 
0.80; Cl 0.61-1.05). 
In this relmspactive analysis of patients with LVD, CCB use was associated 
with significantly increased risk of MI. 
_Ls Th. mmboly~c Therapy Most Effective When 
P.noogenoas Fibdnolysis Is Oeficient? 
Felidta Aedreofti, Gerard Dootjewaa~, Cornalis Kluft, Gilbert R. Thompson, 
Anne Kehely, David R. HaCkett, Graham J. Davies, AtlJlio M&sed. C, at~t/c 
University, Rome. Italy and Hammersmith Hospital, London, UK 
Thmmbi that form as a result of defective endogenous Iti0dnolysis may be 
most sensitive to thmmbolylic agents, Impaired flbfinolytic activity has been 
aSSociated with low plasma levels of single.d~ln urokinase (scu-PA), raised 
I~lxotoin(a) [Lp(a)] and, paradoxically, high t-PA enSgen. 
We invest.~gated the relation between endogenous fibdrmlytic factors on 
admission and subsequent efficacy of thrombolytio therapy in 51 patients 
with acute myocardial infarction (AMI) boated within 6 h of symptoms with 
intravenous rt-PA (20-60 MU) and hepadn, Pm-traatment plasma concen- 
trations of Lp(a) (mg/dl), t-PA antigen lug/L) and urokinase (U-PA, ug/L) were 
measured by ELISAs and of scu-PA lug/L) by bioimmunoassay. A coronary 
artedogram was performed 90 min after the start of lytic therapy. Pedusion 
of the infamt-artsry was defined as TIMI grade 3, 
At 90 rain, a TIMI 3 infarot-erfory was found in 27 pts, The perfosed v,3 
o4:~uded-artew pts did not differ significantly in age, sex, smoking stslus, 
delay to treatment, ime of day of therapy Or rt-PA dose at 90 min. Plasma 
factors (median and interquariffes) were: 
Lp(a) t-PA scu.PA u-PA 
Perfused 16 (11-~2) 26 (17-~) t.9 (1.6--2,1) 2,7 (P-2-,3) 
Occluded 9 (5-27) 15 (10-P.1) P,l(1.g-2.6) 2.6 (2.4-2.8) 
p value 0,02 0.003 0.03 0,38 
Thus, in patients with AMI receiving rt-PA, early coronary mperfusion, cony 
pared with persistent occlusion, is associat~l with higher plasma Lp(a) and 
t-PA antigen levels and lower plasma scu-PA on admission. Phannacotsgical 
doses of rt*PA thus appear most effective when naturalflbdnatysls i def'cteot. 
~ Effect of ProstaWclin in~s ion  as a Treatment of 
Pulmonary Hype~ns ion  
A. Yazdeni Butt, George Cremona, Unda Sharpleo, Arlene McMohan, Tim 
W. Hlgenheftam, Papwodll Hospital, C, ambddge, England, U.K. 
We have examined the alfect of continuous infusion of prostacyclin (PGI~) 
3ACC Febnmry 1996 ABSIRACTS-Poster 37A 
and conventional t l~  (CT) on 131 pa~ants wtllt pulmonary hypedassion 
(PH) [82 females, 49 males; mean age 38 :E 13 years]. Ninely eight patients 
had IXimon/pulrnsnary ~ n  while 33 had thrombo-emb~ic disease. 
Severity of the disease was determined by functional ,class, haemodycand~s 
and mixed venous oxygen saturaZion (SvO~). Patients were categorized into 
group t (SvO~ >_ SO%) and group 2 (SvO= < SO%), and were eitt~ uasted 
with PGI2 or CT. End point was either death, heart-lung Iransplastaflon or 
thrombo.endanerectomy, 
Group 1 (n = s~) Gm.p 2 (n = ~),  , 
PAPm (ram Hg) 60.0 4.16.3 67.~ 4.15,4" 
RAPm (ram Hg) 8.54-6.0 13.44-5.8" 
SvO2 (%) . 6G.54-6.1 50.74-7.2" 
(31 (Ulllin/nt <) 2,01 4- 0.66 1,73 4. 0.46* 
Me~l ~- SD, -p < 0.05 
In group 2, palionts b'e,Med with PGI~ had a greater median sun/ival (239 
days with CT vs, 685 days with PGI~, p < 0,05). There was no significant 
ddferaoca between CT and PGI2 in group 1 (median sun,hr,: 94t days with 
CT vs. 986 days with PGI2). There was no significant (Efference in sundval 
between acute mspondem and aon-mspondere treatod with PGI2; 20% drop 
in pulmonary vascular resistance considered as target dudng dght heart 
calhetedsation ( l, edian suntival: 986 days in acute req)onde~ vs. 786 days 
in norH'esponders; p = 0.228). Continuous in~s~n of PGFa has a role in the 
trcatment of PH where SvO,a is < 60%. Acute vasodilator esponse does nst 
have an effect on the long term outcome of severe PH when treated with 
PGI~. 
VALVULAR DISEASE 
Echocardiographic Score Predicts In-Hospital 
in Patients Undergoing Perculaneous 
Bal loon Mitral Valvuloplasly 
Ma~ J. Eisenberg, Raj Ball~l, Paul ~ Heldonmich, ir.mr~oedy J. Brown, 
Bdan P. Griffin, Murat Tuzcu. Cleveland Clini~ FoundaUon, Cleveland, OH 
Background: Echocardiographic score is known to be pre~ctive of clinical 
ot~:ome in patients undergoing pefcutaneous ballOon mltral va lvu l~ 
(PBMV), but it is unlmown whether this score can also be used to Ixedict 
in4tespitol cost. Met/xxfs: Prepmcedum ~ scores, baseline 
dinlcal chamcted~cs, and total in - t~ costs were examined among 45 
patJests who underwant PBMV between Januaw 1,1992 and Janusxy 1,1995. 
R~ults: Patients ranged in age from 18 to 71 years and had prelxocedum 
echesardingraphic; s ores ranging from 4 to 12. Following PBMV, mean mitra] 
v'al~ area inoreased from 1.1 :E 0.3 fu 2.4:E 0.6 cm 2 (p = 0,0001), and mean 
pressure gradient deareased Irom 18.3 :*: 5.9 to 6.7 ~ 2.7 mm Hg (p = 0.0001). 
In-I Ios~ cost for the 45 paltenls ranged flora $3,591 to $70,975 (mean: 
$9,417; median: $5,311). Univariate and multiple linear regression analyses 
demonstrated ~ among the variables examined, echo~rap ldc  scorn 
(p = 0.0007), age (p = 0.01 ), and pre-procedum itral valve gradiaot (p = 0.03) 
were associated with tn-hospitalcesL Regn~sion modeling suggested thatfur 
evely increase in pre-procedure chocald~ngraphic Score of one grade, there 
was an increase in indlaspi~ cost of $2,663. Condus/on: ECtlOcal~ographic 
score appears to be pred~clJve of in-h0spil~l cast in paf~entS Undergoing PBMV. 
Consequently, patients who have elevated e~¢ardiographi~ scores should 
be slrongly considered for alternative therapy, 
~ Compadson of LOw.Dose and Standard-Dose 
Oral Anticoagulant Therapy in Patients With a 
Mechanical Prosthesis. 1 i~  AREVA Multicenter 
Tdal 
BemanJ lung, Jean Acar, Jean Paul Tefype, Jean Piene Bolsasl, on behalf 
of the invesligafus of the AREVAgroup, Card /~ Depat'anent; H0p#a/ 
Tenon, Paris; SenK~a de Phan~e Clinique, Lyon ~Franoe 
The main puq0ose of the AREVA prospective b'ial was to compare moderate 
oral anticoagulation (INR 2-3) wi~ the usual regimen (INR 3--4.5) after a 
single-valve replacement 0/R) with a mechanical prosthesis, In the infllal 
design of the study, patients (pts) were randomly allocated to receive eilher 
Omnicarbone (OM) or a Saint-Jude (SJ) prosthesis. This allocation was 
suppressed after t year due to problems of availability of OM and all stto- 
Se~!.u~ I~  n~oive¢! .S.J. A~.er VR, pts were ran(~mJzed in the INR target 
r'4nges of 2-3 or 3-4.5. Pts were included if they were ~ged between 18 and 
75 ym, In sinus nJthm, aod if left aMnl diameter wao < 50 m in TM esho, The 
endpoints were thmmbeembolic events as assessed Irom clinical data and 
on CT brain scans, and hemorrhagic events. All blood ~es  cogected for 
INR detenninalJon dudng follow-up (FU) were analyzed, 
From 1991 to 1994, 434 pts underwent VR (aortic 4t5 pts, rnitral 19 pts) 
wilh 354 SJ and 80 OM; 380 were randomized fur INR: 188 for |NR 2-3 
and 192 fur INR 3-4.5. Mean FU was 2.2 [1-4] yrs. From the analysis of 
18002 INR, the mean of the ~ median of INR was 2.80 :E 0.41 inthe 
group 2-3 and 3.23 :~ 0.39 in the group 3-4.5 Co < 0,0001). Results were 
as follows: 
INR 2-3 INR 3-4.5 p 
Pts. wah >_ 1 mrombo.embor¢ event lO 9 0.78 
Pts. wil~ > I major I~event  13 19 0~9 
Pts. with > 1 ~ event 34 ~ O.Ol 
In aondusion, moder'ale ant~ad Jon  allows a de~e~se in gm iaoldence 
of hemonhag~ ~ents, without a~ecling the incidence of thrombeento~ 
evente, in selected pts w~h a mechank~ ixaslbesis, mainly Sj proslbes~ in 
ao~c pesitton. 
~ I)ynamic Orifice Area VariallJons in Functional 
Arnold A. Fonlaino, ~mqiu He, Jeffrey T. Ellis, Ehud Schwammenthal, 
Robert A. Levine, AjitR Yogaoalhan. Georg/a/nst. of Tec~,  Atfat~a, 
GA; M.~---~huse~ Generat -k~., Boston, MA 
Recent stod~ in I~ents w~h hacbenel ~ rngurg~a~ (MR) have 
shown a paradoxical desmase in eWective ~ odfice area (EROA) in 
midsystole desp~ peak driving pmssm~. This behavior soggesto a ~nge 
in the forca balance aclJng on the mi'cal eaflets, with i ~  LV pressure 
counterast~g the lealMchordal tenston that n~ts  ~ hi the d~ated 
LV. Ttds concept was explomd in an in vitro seffing to pemdt independent 
~ofbeth¢~r~glxessumand lea~.d~geometryandtens~ 
(d4icutt in ~o), Seven excised porcine rn~al valves were tested m~cler 
physiologic Puisat~ flow in an LV model; tor e~h, we independency varied 
PM Pesilkm (IX)St., laL and apical oTm~) ,  annular size, aed ddving 
pressure (90-150 mmHg). Instanteneous EROA was calculated ¢Smctly from 
continuity (o~rectly mcasuted MR flow rate/CW ~ or~,ce velocity) and 
;v~.-ec~y from ~ flow and pressure wavefurms (moSSed Bernoulli 
equa~on). The dmaz~ of leaget coalXation wiemut ~ gap was ~ 
by 2D echo. Rest/S: 1 ) ClirdcaUy obaorved eady and late s ~  peaks in 
MR flow and EROA were reproduced by ts0~let te th~ b~ this model, 
with the decrease in EROA c o n ~  to ds~ng LV ddving pressure, 2) 
Greater k~mm ~ mod,e~ Zncmased the eady sys~ ~ 
closing volume before completo couplal~n (delayed v',dve cJusum). 3) MR 
increased as dura~an of lealtel o o ~  deoreased (r = 0,61), 
EROs. vz Svst~k: Time 
OS Peak DltVl~lPiessom 159 
c~ -tO ~ azd .[ I 
v 
0 30 ~ g(I lr~lSOll;ZlO;;Mo;rtQ3/30330 
Systd~ Time (ms) 
Conc/~s/ons: Dynsmic v~alJon of EROA can be mprnduced invilroby 
inc~_ __ ~,d leallet elhedng and phasic LV pressure, consistant wilh a mecha- 
nism in whid~ an a / t~ foce ba/arce a~/ng on the /ea~ ( ~  ~s  
co~ng) is central to cmating ~ MR EROA. 
VASCULAR/CORONARY DISEASFJTHROMBOSIS- 
BASIC 
Rapid Aottvatkm of MitogewAcU~rated Protein 
Kinase (MAPK) by Balloon Angioplasty of in Vivo 
Pordne Coronary and Carotid Arteries 
J. Mario Pyles, Michaet T. Frankrm, Khtwrar Metal, Robert L Wilansky, 
Leonard R Adam, ~ L Mamh. Krarme~ institute of ~ and RL 
Roude~ssh VN~C, ~ IN: Boston ek~ed~aS Research Zm#tuto, 
Boston, MA 
Vasc~ar restano~ involves contmc~le, proliferate, and remodeling re- 
sponses of the aderis] wall to ovecstmtch injury. MAPK is hnldicateci in 
contraclge and ixolifera~e responses of vascular smooth muscle. Studies 
of ixm ine carotid ~ s t~ have shown t~at mechanical stretch leads 
to the acSva~m of MAPK in vitro. We themfuns analyzed the acute effect 
of mecRBnical ove~lmtch on MAPK activity in porcine coronary and carotid 
artedas in vivo. 
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